Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation
- PMID: 16049701
- DOI: 10.1007/s00228-005-0927-4
Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation
Abstract
Objective: To investigate the population pharmacokinetics of mycophenolic acid (MPA) in adult kidney transplant recipients during the crucial first week after transplantation.
Methods: Data were collected from 117 patients. MPA plasma concentrations were determined at t=0, 1, 2, 3 and 4 h after mycophenolate mofetil dosing on days 3, 5 and 7. Population analysis was performed using NONMEM. Covariates screened were sex, age, body weight, serum creatinine, creatinine clearance, serum albumin, days of therapy, diabetes mellitus, organ source (live or cadaveric) and co-therapy (tacrolimus or cyclosporine). Final model validity was evaluated using 200 boot strapped samples from the original data. Bias and precision were determined through comparison of observed and predicted concentrations.
Results: Individual concentration-time profiles showed evidence of an absorption lag time and enterohepatic recirculation of MPA in some patients on some occasions. The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%). CL/F decreased significantly with increasing serum albumin (1.42 l/h reduction in total plasma CL/F with each 1 g/l increase in albumin) and was 27% greater in patients receiving cyclosporine than in those receiving tacrolimus. Evaluation of the final model showed close agreement between pairs of boot strapped and final model parameter estimates (all differences <7%). Predictions were non-biased (0.11 mg/l) but imprecise (2.8 mg/l).
Conclusion: Population pharmacokinetic parameters for MPA were determined. These can be used to achieve specific target MPA concentrations or areas under the concentration-time curve.
Similar articles
-
Population pharmacokinetics of mycophenolic acid in renal transplant recipients.Clin Pharmacokinet. 2005;44(10):1083-96. doi: 10.2165/00003088-200544100-00006. Clin Pharmacokinet. 2005. PMID: 16176120
-
Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.Ther Drug Monit. 2010 Oct;32(5):606-14. doi: 10.1097/FTD.0b013e3181efd715. Ther Drug Monit. 2010. PMID: 20720518
-
Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach.Ren Fail. 2015 May;37(4):652-8. doi: 10.3109/0886022X.2015.1010442. Epub 2015 Feb 24. Ren Fail. 2015. PMID: 25707517 Clinical Trial.
-
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28. Transplant Rev (Orlando). 2011. PMID: 21190834
-
Population Pharmacokinetics of Mycophenolic Acid: An Update.Clin Pharmacokinet. 2018 May;57(5):547-558. doi: 10.1007/s40262-017-0593-6. Clin Pharmacokinet. 2018. PMID: 28861847
Cited by
-
Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus.Br J Clin Pharmacol. 2019 Apr;85(4):746-761. doi: 10.1111/bcp.13850. Epub 2019 Feb 5. Br J Clin Pharmacol. 2019. PMID: 30597603 Free PMC article.
-
Does Age Influence Immunosuppressant Drug Pharmacokinetics in Kidney Transplant Recipients?Eur J Drug Metab Pharmacokinet. 2024 Nov;49(6):751-761. doi: 10.1007/s13318-024-00914-3. Epub 2024 Aug 29. Eur J Drug Metab Pharmacokinet. 2024. PMID: 39210243 Free PMC article.
-
Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.Br J Clin Pharmacol. 2012 May;73(5):727-40. doi: 10.1111/j.1365-2125.2011.04140.x. Br J Clin Pharmacol. 2012. PMID: 22053944 Free PMC article.
-
Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.Eur J Clin Pharmacol. 2018 May;74(5):583-591. doi: 10.1007/s00228-018-2414-8. Epub 2018 Jan 16. Eur J Clin Pharmacol. 2018. PMID: 29340733
-
The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.Clin Pharmacokinet. 2011 Jan;50(1):1-24. doi: 10.2165/11536640-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21142265 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical